Emily Collins, Nutrition Researcher (Supplements & Superfoods)

📚 Researched & cited by UV Editorial Team Independently reviewed · Last updated: May 29, 2026 · Our research methodology → Reference page for clinicians, patients, and journalists: every common GLP-1 receptor agonist side effect, the % incidence rate from registration trials, and the evidence-anchored supplement category that addresses it. Each row links to UV’s

Pick your GLP-1 drug, the side effects you’re managing, and your goals. The tool returns a personalized supplement stack with evidence-anchored picks linking to our full UV reviews. This tool gives supplement-stack starting points, not medical advice. Discuss any supplement plan with your prescriber, especially if you have kidney disease, take other medications, or are

If you have been scrolling Amazon or Whole Foods and seeing Vital Proteins on every collagen display and wondering whether the brand premium actually delivers something the cheaper tubs do not, the short answer is: Vital Proteins is a legitimately good product, but the premium is mostly paying for brand reach, not dramatically better biochemistry.

If you have been comparing collagen brands and seeing Momentous keep appearing on athlete Twitter, in NSF-certification discussions, and in the Instagram feeds of professional trainers, the short answer is: Momentous is a legitimately premium product whose value depends almost entirely on whether you need NSF Certified for Sport screening. The peptide is high quality,

Which US state Medicaid programs cover Wegovy, Zepbound, or Saxenda for adult obesity in 2026? Color-coded tile map, sortable per-state table, BMI thresholds, prior-authorization criteria, and the coverage growth trend since 2022. Updated quarterly. State Medicaid drug coverage policies change monthly. The data below is based on publicly available Medicaid Preferred Drug Lists (PDLs), KFF

Chronological reference of FDA actions and major court rulings affecting compounded semaglutide and tirzepatide from the start of the GLP-1 shortages (2022) through April 2026. Each event has its own permalink anchor and is sourced to FDA documents, court filings, or contemporaneous coverage. Last updated: 2026-04-27. The compounded-GLP-1 enforcement story is still unfolding — we

📚 Researched & cited by UV Editorial Team Independently reviewed · Last updated: May 29, 2026 · Our research methodology → Citable numbers on GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide) — market size, prescription volume, user demographics, clinical outcomes, pricing, insurance, side effects, and regulatory actions. Every stat is sourced. Use the anchor